Alexion appoints new senior VP for EMEAC region

Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

She will lead the commercial activities of the regional function from Alexion’s EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.

Regarding her new role, Hartvig said: “I am delighted to join the great team in this region, that is a strategic pillar for Alexion accounting for more than a third of Alexion’s global business, and look forward to stewarding the company’s growth and development hire in the years ahead.”

Hartvig, who has more than 20 years’ experience in the pharmaceutical industry, has worked in a broad spectrum of companies, including AstraZeneca, Novartis and Allergan.

Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.

She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.